U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07050316) titled 'Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects' on April 30.
Brief Summary: A Phase 1, Randomized, Double-Blinded, Placebo-Controlled study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multiple Ascending Doses of CBT101 given intranasally in Healthy Male Subjects.
Study Start Date: March 14
Study Type: INTERVENTIONAL
Condition:
Neurologic Diseases, General
Intervention:
DRUG: CBT101
Part 1 (SAD): at the morning
* Cohort 1: 1 puff in each nostril (total 2 puffs), total 4.2 mg
* Cohort 2: 2 puffs in each nostril (total 4 puffs), total 8.4 mg
* Cohort 3: 3 puffs...